Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Avalo Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 71 | 1 | 54 | −16 |
| Shares | 77.7M | 9.81K | 69.4M | −8.31M (−10.7%) |
| Value | $56.2M | $7.00K | $34.7M | −$21.5M (−38.2%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Avalo Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 1,011,082 | $506.0K | 0.00% |
| Ergoteles LLC | 284,569 | $142.0K | 0.00% |
| Qube Research & Technologies Ltd | 44,308 | $22.0K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 26,079 | $13.0K | 0.00% |
| Orion Portfolio Solutions, LLC | 25,476 | $13.0K | 0.00% |
| Balyasny Asset Management LLC | 15,995 | $8.00K | 0.00% |
| Credit Suisse AG | 33 | $0 | 0.00% |
| Simplex Trading, LLC | 400 | $0 | 0.00% |
Sold out (24)
Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Boothbay Fund Management, LLC | 1,198,757 | $869.0K |
| Ikarian Capital, LLC | 764,271 | $554.0K |
| Integral Health Asset Management, LLC | 700,000 | $507.0K |
| Nuveen Asset Management, LLC | 405,047 | $294.0K |
| Two Sigma Advisers, LP | 209,900 | $152.0K |
| Deutsche Bank AG | 112,925 | $82.0K |
| Two Sigma Investments, LP | 70,703 | $51.0K |
| BFT Financial Group, LLC | 62,629 | $45.0K |
| Rhumbline Advisers | 49,728 | $36.0K |
| Assenagon Asset Management S.A. | 42,338 | $31.0K |
| STRS Ohio | 38,400 | $27.0K |
| American International Group, Inc. | 30,933 | $22.0K |
| California State Teachers Retirement System | 26,713 | $19.0K |
| Tamar Securities, LLC | 23,084 | $17.0K |
| Invesco Ltd. | 19,173 | $14.0K |
| Alliancebernstein L.P. | 19,200 | $14.0K |
| Gyon Technologies Capital Management, LP | 18,242 | $13.0K |
| Susquehanna International Group, LLP | 14,763 | $11.0K |
| Tower Research Capital LLC (TRC) | 14,549 | $11.0K |
| ProShare Advisors LLC | 11,679 | $8.00K |
| Amalgamated Bank | 9,807 | $7.00K |
| Brewin Dolphin Ltd | 9,300 | $7.00K |
| Nisa Investment Advisors, LLC | 2,990 | $2.00K |
| Ameritas Investment Partners, Inc. | 1,893 | $1.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 9,807 | $7.00K |